Filing Analysis
The Joint Corp. (JYNT) filed an 8-K to announce its quarterly financial results for the period ended June 30, 2026 and provided a corresponding earnings presentation.
📋 Key Facts
- Reported on August 6, 2026.
- Quarterly financial results announced for the quarter ended June 30, 2026 (Item 2.02).
- Earnings presentation provided via Exhibit 99.2 (Item 7.01).
- Signed by Sanjiv Razdan, President and CEO.
The Joint Corp. reported the voting results from its 2026 annual meeting of stockholders held on May 20, 2026. Stockholders elected seven directors, approved executive compensation on an advisory basis, selected an annual frequency for future executive compensation votes, and ratified the appointment of BDO USA, P.C. as the company's independent auditor for 2026.
📋 Key Facts
- The annual meeting of stockholders was held on May 20, 2026.
- Seven directors were elected to serve until the 2027 annual meeting: Matthew E. Rubel, Ronald V. DaVella, Jefferson Gramm, Christopher M. Grandpre, Sandra R.A. Karrmann, Milind Pant, and Sanjiv Razdan.
- Advisory vote on executive compensation was approved with 10,511,822 votes for and 342,867 votes against.
- Stockholders voted in favor of holding future advisory votes on executive compensation on an annual basis (10,377,647 votes).
- The appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 12,716,958 votes for.
The Joint Corp. entered into a waiver and fourth amendment to its credit agreement with JPMorgan Chase to address an existing default resulting from a violation of its fixed charge coverage ratio covenant. The amendment waives the default, modifies the covenant to permit stock repurchases, and extends the revolving credit maturity date to August 31, 2029.
🚩 Red Flags
- Existing default of credit facilities due to covenant violation (fixed charge coverage ratio).
- Multiple 8-K items triggered in a single filing (1.01, 2.02, 2.03, 7.01).
📋 Key Facts
- Company entered into a Waiver and Fourth Amendment to its credit agreement with JPMorgan Chase on May 1, 2026.
- The amendment waives an existing default caused by a violation of the fixed charge coverage ratio covenant.
- The revolving credit maturity date was extended to August 31, 2029.
- The amendment modifies the fixed charge coverage ratio to allow for stock repurchases, classified as restricted payments.
- The filing coincides with the release of Q1 2026 financial results on May 7, 2026.
The Joint Corp. has commenced the divestiture of 45 company-owned or managed clinics in Southern California to Elite Chiro Group for $2.3 million. As of April 27, 2026, 13 clinics have officially closed, while the remaining 32 are being managed under a service agreement pending lease assignments.
🚩 Red Flags
- Low valuation of approximately $51,000 per clinic suggests the locations may be underperforming or the sale is distressed.
- Execution risk remains for the 32 clinics currently under MSA, as closing is 'expressly conditioned' upon third-party lease assignments.
📋 Key Facts
- Total transaction involves 45 clinics for an aggregate price of $2.3 million, roughly $51,111 per clinic.
- 13 clinics closed on April 27, 2026, with ownership transferred to Elite Chiro Group.
- 32 clinics are currently under a Management Service Agreement (MSA) until lease assignments are finalized.
- The buyer, Elite Chiro Group, is also being granted franchise rights for these locations.
- Gadi Emein is acting as the guarantor for the buyer.
The Joint Corp. entered into an Asset Purchase Agreement to sell 45 company-owned or managed clinics in Southern California to Elite Chiro Group for $2.3 million. This transaction represents a strategic shift toward a franchised model for these locations and includes development rights for 10 additional clinics.
🚩 Red Flags
- Low valuation per unit: The $2.3 million price for 45 clinics equates to approximately $51,111 per location, which may indicate the corporate-owned clinics were underperforming or the company is prioritizing a quick exit from corporate operations.
📋 Key Facts
- Agreement dated April 20, 2026, with Elite Chiro Group and guarantor Gadi Emein.
- Sale involves 45 clinics in Southern California for an aggregate price of $2.3 million.
- The purchase price includes prorated franchise fees and non-exclusive development rights for 10 new clinics.
- A $150,000 non-refundable down payment was made for exclusivity.
- Closing for each clinic is contingent upon the successful assignment of existing leases.
- The remaining balance of the purchase price will be held in escrow and released as individual clinic closings occur.
The Joint Corp. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing includes a press release and an earnings presentation intended for use during the company's investor conference call.
📋 Key Facts
- Announced Q4 and FY 2025 financial results on March 12, 2026.
- Furnished a press release as Exhibit 99.1.
- Posted an earnings presentation to the company's investor relations website as Exhibit 99.2.
- The report was signed by President and CEO Sanjiv Razdan.
The company filed an 8-K/A to amend a previous filing, correcting the summary of a letter agreement with Bandera Partners LLC and Jefferson Gramm. The agreement involves nominating Mr. Gramm for the Board of Directors at the 2026 Annual Meeting and includes beneficial ownership restrictions.
🚩 Red Flags
- Amendment filing (8-K/A) indicates previous disclosure errors regarding material agreements.
- Presence of a significant shareholder (Bandera Partners LLC) negotiating board seats often signals potential activist involvement or shifts in corporate control.
📋 Key Facts
- Amends an original 8-K filed on January 5, 2026 (re-filed as 8-K/A).
- The company entered into a Letter Agreement with Bandera Partners LLC and Jefferson Gramm on January 5, 2026.
- The agreement includes the nomination of Mr. Gramm to the Board of Directors for the 2026 Annual Meeting.
- Bandera is restricted from acquiring beneficial ownership exceeding 3,937,296 shares (excluding awards/grants) until the Termination Date.
- The agreement expires on either January 21, 2027, or 30 days prior to the 2027 Annual Meeting nomination deadline.
The Joint Corp. entered into a Letter Agreement with Bandera Partners LLC and Jefferson Gramm on January 5, 2026. The agreement involves nominating Mr. Gramm to the Board of Directors at the 2026 Annual Meeting and includes voting commitments and standstill obligations.
🚩 Red Flags
- Presence of 'standstill obligations' and 'voting commitments' often indicates a negotiated settlement with an activist investor to avoid a proxy contest.
📋 Key Facts
- Entered into a Letter Agreement with Bandera Partners LLC and Jefferson Gramm on January 5, 2026.
- The company will include Jefferson Gramm in its slate of nominees for the 2026 Annual Meeting of stockholders.
- The agreement includes voting commitments and standstill obligations by Bandera.
- Includes restrictions on the transfer of common stock held by Bandera until a Termination Date.
- Termination Date is set for either 30 days prior to the 2027 nomination deadline or January 21, 2027.
The Joint Corp. has entered into an agreement to sell 22 clinics in the Southeast region for $1.48 million and simultaneously terminated a larger $4.5 million asset purchase agreement with Elite Chiro Group due to failure to meet closing conditions.
🚩 Red Flags
- Significant loss of potential revenue/assets: The termination of the Elite Chiro Group deal represents a loss of a $4.5M transaction (nearly 3x the size of the new deal).
- Transaction instability: Multiple material agreements being entered into and terminated within a short window suggests difficulty in closing large asset sales.
- Conditional nature of deals: The new Southeast deal is heavily contingent on lease assignments for at least 17 of the 22 clinics.
📋 Key Facts
- Entered into Asset Purchase Agreement with Addisco Value, LLC and others on Dec 5, 2025.
- Sale of assets/franchise rights for 22 clinics in VA, NC, and SC.
- Aggregate purchase price: $1,482,800 (comprising $1M cash, $667,800 in franchise fees, less $185,000 renovation credit).
- Terminated the Elite Chiro Group Purchase Agreement (dated Nov 2, 2025) for 45 clinics in Southern California.
- The terminated deal was valued at $4.5 million and failed due to buyer's failure to meet closing conditions.
The Joint Corp. has entered into an agreement to sell 45 company-owned or managed clinics in Southern California to Elite Chiro Group for a total of $4.5 million. This significant divestiture includes both asset sales and the granting of franchise rights, while simultaneously authorizing an additional $12 million for stock repurchases.
🚩 Red Flags
- Significant asset disposition: Selling 45 company-owned/managed clinics suggests a strategic shift or potential liquidity need.
- Contingency risk: The deal relies heavily on the successful assignment of leases for at least 84% (38 of 45) of the locations.
- Guarantor reliance: The agreement is personally guaranteed by an individual, Gadi Emein, rather than a corporate entity.
📋 Key Facts
- Sale of 45 clinics in Southern California to Elite Chiro Group for a total price of $4.5 million.
- Purchase price structure: $3,154,500 in cash and $1,345,500 in prorated franchise fees.
- A non-refundable down payment of $100,000 is required for exclusivity.
- The transaction includes the acquisition of non-exclusive development rights for 10 clinics by the buyer for a $90,000 fee.
- Transaction is contingent upon the assignment of existing leases for at least 38 of the 45 clinics.
- Board authorized an additional $12.0 million for its stock repurchase program through November 4, 2027.
The Joint Corp. entered into a third amendment and consent to its existing credit agreement with JPMorgan Chase Bank on September 30, 2025. The amendment focuses on refranchising company-owned clinics and extending the revolving credit maturity date.
🚩 Red Flags
- Strategic shift toward 'refranchising' often indicates a need to reduce capital expenditure or improve liquidity by offloading asset ownership.
📋 Key Facts
- Entered into '2025 Amendment' with JPMorgan Chase Bank, N.A. on September 30, 2025.
- The amendment provides consent for the refranchising of all company-owned or managed clinics.
- The revolving credit maturity date has been extended to August 31, 2027.
- The agreement includes customary representations and warranties.
The Joint Corp. has entered into a separation agreement with its former Chief Financial Officer, Jake Singleton, following his resignation effective June 9, 2025.
🚩 Red Flags
- Departure of a key executive (CFO) can sometimes signal internal friction or financial reporting concerns, though not explicitly stated here.
- The effective date of departure (June 9) is significantly earlier than the filing/agreement date (August 22), indicating a delayed formalization of terms.
📋 Key Facts
- Mr. Singleton's role as CFO ceased effective June 9, 2025.
- Separation Agreement includes a general release of all claims signed on August 22, 2025.
- Severance package includes six months of base salary and $15,000 in additional cash.
- The company will pay for accumulated time off totaling $36,193.99.
- The company will cover up to six months of COBRA health insurance costs.
- No accelerated vesting was granted for outstanding equity awards.
The Joint Corp. (JYNT) filed an 8-K to announce its quarterly financial results for the period ended June 30, 2025 and provided a corresponding earnings presentation.
📋 Key Facts
- Reported date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- Included Exhibit 99.1 (Press Release) and Exhibit 99.2 (Earnings Presentation)
- Information furnished under Items 2.02 and 7.01 is not deemed 'filed' for purposes of Section 18 liability.
JOINT Corp. has announced that its previously issued financial statements for the fiscal year ended December 31, 2024, and the quarter ended March 31, 2025, contain material errors and should no longer be relied upon. The errors stem from a misapplication of GAAP regarding impairment valuations for assets held for sale in discontinued operations.
🚩 Red Flags
- Material error identified in previously issued audited and unaudited financial statements (Item 4.02).
- Expected material weakness in internal control over financial reporting.
- Ineffective disclosure controls and procedures during the applicable periods.
- Potential for future class action lawsuits mentioned in forward-looking risk factors.
📋 Key Facts
- The company will restate its Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the period ended March 31, 2025.
- Estimated impact for FY2024: A $2.2 million reduction in reported loss from discontinued operations (before income taxes) and a $2.2 million increase in carrying value of assets held for sale.
- Estimated impact for Q1 2025: A $0.5 million increase in net income and a cumulative $2.7 million increase in the carrying value of assets held for sale.
- The errors are expected to result in a material weakness in internal control over financial reporting and ineffective disclosure controls/procedures.
- The adjustments are non-cash and are not expected to impact Adjusted EBITDA or cash/cash equivalents.
The Joint Corp. completed the sale of 31 company-owned clinics in Arizona and New Mexico to its largest franchisee, Joint Ventures, LLC, for $11.13 million. As part of the deal, the company also acquired regional developer rights for the Northwest Region.
🚩 Red Flags
- Asset disposition of core operating units (31 company-owned clinics) may indicate a shift toward a capital-light model or a need for immediate liquidity.
- Transaction is with the largest franchisee, which could represent a related-party dependency or concentration risk.
📋 Key Facts
- Completed sale of assets/franchise rights for 31 clinics in AZ and NM on June 30, 2025.
- Aggregate purchase price is $11.13 million (subject to adjustments).
- Buyer is Joint Ventures, LLC, identified as the company's largest franchisee.
- Acquired regional developer rights for Northwest Region (46 existing franchised clinics and 30 future sites) in CA, UT, NV, WA, and OR.
The Joint Corp. entered into an agreement to sell 31 company-owned clinics in Arizona and New Mexico for $11.07 million while simultaneously acquiring regional developer rights for the Northwest Region. Additionally, the company completed a separate sale of five clinics in Kansas and Missouri.
🚩 Red Flags
- Significant asset disposition: The company is selling off a substantial portion of its owned/managed clinic footprint (31 clinics).
- Multiple material events in a single filing (Item 1.01 and Item 8.01) indicating rapid restructuring or liquidity needs.
- Shift in business model from direct ownership to a franchise/developer-centric model, which can lead to volatility in revenue recognition.
📋 Key Facts
- Entered into Asset Purchase Agreement with Joint Ventures, LLC on June 23, 2025.
- Sale of 31 company-owned/managed clinics in AZ and NM for an aggregate price of $11.07 million (subject to adjustments).
- Acquisition of regional developer rights for the Northwest Region (46 existing franchised clinics + 30 future sites) covering CA, UT, NV, WA, and OR.
- Completed sale of 5 clinics in KS and MO to 93 Chiro, LLC on June 23, 2025.
- Joint Ventures Transaction expected to close by June 30, 2025.
The Joint Corp. announced the separation of CFO Jake Singleton effective June 9, 2025, and the appointment of Scott J. Bowman as the new CFO effective June 10, 2025.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (CFO).
📋 Key Facts
- Jake Singleton separated from the company as CFO on June 9, 2025.
- Scott J. Bowman appointed as CFO effective June 10, 2025.
- Bowman's compensation includes an annual base salary of $390,000 and an initial stock grant valued at $250,000 under the 2024 Incentive Stock Plan.
- Bowman brings significant public company experience from Leslie’s, Inc., True Food Kitchen, Dave & Buster’s Entertainment, Inc., Hibbett, Inc., The Home Depot, and The Sherwin-Williams Company.
The Joint Corp. announced the appointment of Sandra R.A. Karrmann to its Board of Directors, where she will chair the Compensation Committee. Additionally, the Board approved a $5.0 million stock repurchase program authorized through June 2027.
📋 Key Facts
- Sandra R.A. Karrmann appointed to the Board effective June 3, 2025.
- Ms. Karrmann will serve as Chair of the Compensation Committee.
- Board approved a stock repurchase plan for up to $5.0 million of common stock.
- Repurchase authorization is valid until June 3, 2027, or until funds are exhausted/terminated.
The Joint Corp. held its 2025 annual meeting of stockholders on May 21, 2025. Shareholders approved the election of seven directors, advisory compensation for named executive officers, and the ratification of BDO USA, P.C. as independent auditors.
📋 Key Facts
- Annual meeting held on May 21, 2025.
- Seven nominees were elected to the Board of Directors: Matthew E. Rubel, Ronald V. DaVella, Suzanne M. Decker, Jefferson Gramm, Christopher M. Grandpre, Abraham Hong, and Sanjiv Razdan.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The Joint Corp. filed an 8-K to announce its financial results for the quarter ended March 31, 2025 and provided an earnings presentation.
📋 Key Facts
- Reported date: May 8, 2025
- Reporting period: Quarter ended March 31, 2025
- Included Exhibit 99.1 (Press Release) and Exhibit 99.2 (Earnings Presentation)
- The filing is primarily for the purpose of furnishing earnings results under Items 2.02 and 7.01.
The Joint Corp. announced its fourth quarter and full year 2024 financial results and updated the terms of its Executive Short-Term Incentive Plan (STIP). The update introduces performance-based bonus thresholds tied to Adjusted EBITDA for the CEO and CFO.
🚩 Red Flags
- The incentive structure is heavily tied to 'Adjusted EBITDA,' which can be subject to management discretion and non-GAAP adjustments.
📋 Key Facts
- Announced Q4 and Full Year 2024 financial results on March 13, 2025.
- Amended the Executive STIP to include cash compensation eligibility for the CEO and CFO based on Adjusted EBITDA targets.
- Established an 'Award Threshold' where the bonus pool is only funded if actual performance reaches at least 85% of the Combined Pool Maximum.
- CEO targeted STIP award capped at 100% of base salary, with a potential increase to 125% if Revised Adjusted EBITDA exceeds budgeted targets.
- CFO targeted STIP award capped at 50% of base salary, with a potential increase to 62.5% under the same performance conditions.
The Joint Corp. issued a press release announcing its operating metrics for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: January 16, 2025
- Subject matter: Announcement of 2024 full-year operating metrics
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
The Joint Corp. entered into an Amended and Restated Nomination and Standstill Agreement with Bandera Partners LLC on December 19, 2024. The agreement involves the inclusion of Mr. Gramm in the company's slate of director nominees for the 2025 Annual Meeting and provides for certain director replacement rights.
🚩 Red Flags
- Presence of a 'Standstill Agreement' often indicates past or ongoing proxy contests/activist investor involvement
- Restrictions on stock transfers by the counterparty (Bandera) can impact liquidity and market perception
📋 Key Facts
- Agreement date: December 19, 2024
- Parties involved: The Joint Corp. and Bandera Partners LLC (and affiliates)
- Key provision: Inclusion of Mr. Gramm in the slate of nominees for the 2025 Annual Meeting of stockholders
- The agreement includes voting commitments and standstill obligations by Bandera
- Includes restrictions on the transfer of common stock held by Bandera
- Agreement expiration: Earlier of January 2, 2026, or 30 days prior to the 2026 annual meeting nomination deadline
- Contains mutual non-disparagement provisions
The Joint Corp. filed an 8-K to announce its quarterly financial results for the period ended September 30, 2024. The filing includes a press release and an earnings presentation as exhibits.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Quarter ended September 30, 2024
- Included Exhibit 99.1: Press Release regarding financial results
- Included Exhibit 99.2: Earnings presentation for use in conference calls and investor communications
The Joint Corp. announced a leadership transition involving the resignation of CEO Peter D. Holt effective October 10, 2024, and the appointment of Sanjiv Razdan as the new President and CEO effective October 14, 2024.
🚩 Red Flags
- Sudden departure of the CEO and Board member (Peter D. Holt).
- Significant cash severance/separation package for outgoing CEO.
📋 Key Facts
- CEO Peter D. Holt resigned from his roles as President, CEO, and Board member on Oct 10, 2024.
- Holt's separation agreement includes 12 months of base salary, 6 months of COBRA premiums, and a $94,000 payment for short-term incentives.
- Sanjiv Razdan appointed as President, CEO, and Board member effective Oct 14, 2024.
- Razdan's compensation includes a $550,000 annual base salary and an inducement grant of stock options/restricted stock worth $800,000.
- Razdan brings significant industry experience from Coffee Bean & Tea Leaf, Sweetgreen, Applebee’s, and YUM Brands.
The Joint Corp. (JYNT) filed an 8-K to announce its quarterly financial results for the period ending June 30, 2024 and provided a corresponding earnings presentation.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- Includes press release (Exhibit 99.1) and earnings presentation (Exhibit 99.2)
- CEO Peter D. Holt signed the filing
The Joint Corp. held its 2024 annual meeting of stockholders on May 22, 2024. Stockholders approved the election of seven directors, advisory compensation for named executive officers, the appointment of BDO USA, P.C. as independent auditors, and the 2024 Incentive Stock Plan.
🚩 Red Flags
- Proposal 4 (Stock Plan approval) received a significant number of 'Against' votes (2,307,064), though it passed with the majority.
📋 Key Facts
- Annual meeting held on May 22, 2024.
- Seven nominees were elected to the Board of Directors for terms expiring in 2025 or until successors are elected.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- The 2024 Incentive Stock Plan (Proposal 4) was approved by stockholders.
The Joint Corp. filed an 8-K to announce its financial results for the quarter ended March 31, 2024 and provided an earnings presentation.
📋 Key Facts
- Report date: May 2, 2024
- Quarterly period covered: Quarter ended March 31, 2024
- Included Exhibit 99.1 (Press Release) and Exhibit 99.2 (Earnings Presentation)
- The filing is a standard earnings announcement under Items 2.02 and 7.01.
The Joint Corp. has filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023. The filing includes a press release and an earnings presentation.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Filing date: March 7, 2024.
- Included exhibits: Press release (99.1) and Earnings Presentation (99.2).
- The information provided under Items 2.02 and 7.01 is furnished, not filed.